BRIEF-EMA Gets Application For Conditional Marketing Authorisation...

From EU COST Fin-AI
Revision as of 02:13, 6 May 2021 by IsabellaColwell (talk | contribs) (Created page with "<br>Jan 12 (Reuters) - European Medicines Agency:<br> <br>* EMA SAYS RECEIVED AN APPLICATION FOR CONDITIONAL MARKETING AUTHORISATION (CMA) FOR A COVID-19 VACCINE DEVELOPED BY...")
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search


Jan 12 (Reuters) - European Medicines Agency:

* EMA SAYS RECEIVED AN APPLICATION FOR CONDITIONAL MARKETING AUTHORISATION (CMA) FOR A COVID-19 VACCINE DEVELOPED BY ASTRAZENECA AND OXFORD UNIVERSITY

* ASSESSMENT OF THE VACCINE, KNOWN AS COVID-19 VACCINE ASTRAZENECA, WILL PROCEED UNDER AN ACCELERATED TIMELINE

* ASSESSMENT OF VACCINE, panel pulsa termurah KNOWN AS COVID-19 VACCINE ASTRAZENECA, WILL PROCEED UNDER AN ACCELERATED TIMELINE

* EMA SAYS AN OPINION ON MARKETING AUTHORISATION COULD BE ISSUED BY 29 JANUARY DURING MEETING OF EMA'S SCIENTIFIC COMMITTEE FOR HUMAN MEDICINES (CHMP)

* ADDITIONAL SCIENTIFIC INFO ON ISSUES RELATED TO QUALITY, SAFETY, EFFICACY OF VACCINE PROVIDED BY ASTRAZENECA AT REQUEST OF CHMP, CURRENTLY BEING ASSESSED Source text: website Further company coverage:

Retrieved from "https://wiki.fin-ai.eu/index.php?title=BRIEF-EMA_Gets_Application_For_Conditional_Marketing_Authorisation...&oldid=3497"